August 2026 brought a steady stream of biopharma deals, reflecting ongoing research collaborations, particularly in oncology and metabolic diseases. Despite the season’s slower pace, American companies led the charge, closely followed by biotechs from the Asia Pacific region.
Major Acquisitions
Leading the acquisitions was Eli Lilly’s purchase of Merida Biosciences for up to $2.875 billion. Based in Massachusetts, Merida focuses on engineered proteins targeting antibodies linked to autoimmune and allergic conditions. Its flagship candidate is a fusion protein aimed at treating Graves’ disease and thyroid eye disease, both of which impact thyroid function. This acquisition follows Lilly’s notable $3.8 billion buyout of Atai Beckley, a mental health therapeutics company, just a month prior.
In another significant move, Jazz Pharmaceuticals from Ireland acquired California’s Actio Biosciences for $820 million upfront, with potential additional payments of up to $500 million. Actio is developing an ion channel inhibitor for epilepsy, a neurological disorder. Jazz recently collaborated with AbCellera to enhance its antibody development initiatives.
Tarsus Pharmaceuticals, also based in California, took over Alkeus Pharmaceuticals, which specializes in treatments for ocular disorders. This deal is valued at $450 million upfront, with an additional $350 million tied to milestones. Tarsus aims to advance Alkeus’ phase 2 small molecule targeting Stargardt disease, which leads to vision impairment.
Strategic Partnerships
Copenhagen’s LEO Pharma acquired Tanabe Pharma’s small molecule for $435 million. This compound, known as dersimelagon, is an oral melanocortin 1 receptor agonist that has successfully completed phase 3 trials for erythropoietic protoporphyria and X-linked protoporphyria. With FDA approval anticipated, LEO Pharma is poised to manage its commercialization, following their acquisition of Replay’s gene therapy pipeline earlier this year.
Massachusetts-based Werewolf Therapeutics merged with Ambros Therapeutics, a California-based developer focusing on pain therapies. Ambros is advancing neridronate, a small molecule in phase 3 trials for complex regional pain syndrome type 1. While financial terms were not disclosed, Ambros recently raised $150 million through a private placement.
Fulcrum Therapeutics and Slate Medicines, based in North Carolina, also combined forces, although financial details remain undisclosed. The merged organization, operating under Slate Medicines, will prioritize the development of SLTE-1009, a monoclonal antibody in phase 1 trials intended to prevent migraines and other headache disorders.
Innovative Collaborations
In a notable billion-dollar collaboration, Genentech, a Roche subsidiary, partnered with DualityBio from Shanghai to develop antibody-drug conjugates (ADCs) using DualityBio’s DUPAC platform. The deal allows DualityBio to discover ADCs and transition them through initial clinical studies, while Genentech will manage later-stage development and commercialization, potentially yielding over $1 billion.
Pathos AI from Illinois entered a collaboration with Alphamab Biopharmaceuticals to develop the bispecific antibody-drug conjugate JSKN016 for cancer. This agreement grants Pathos AI rights for research, development, and commercialization outside of China, with Alphamab set to receive $125 million upfront and up to $2.093 billion in milestone payments.
Ongoing Research Initiatives
Genentech’s additional deal involved a peptide therapy from Hanmi Pharm in Seoul, targeting obesity, type 2 diabetes, and heart diseases. Hanmi will continue development through phase 1 trials before transferring the drug to Genentech, except in South Korea. The deal is valued at $190 million upfront, with a total potential value of $2.3 billion.
Japan’s Ono Pharmaceutical partnered with Mediar Therapeutics from Massachusetts to develop treatments for fibrotic diseases. Ono has secured the option for worldwide rights to develop drugs targeting myofibroblast cells, although the upfront fee remains undisclosed.
SK Biopharmaceuticals from South Korea reached an agreement with Connecticut’s Biohaven for the Kv7 ion channel platform and the epilepsy candidate opakalim. The deal grants SK Biopharmaceuticals rights to develop the oral potassium channel activator currently in phase 2/3 trials, with Biohaven positioned to receive up to $795 million.
In another promising partnership, Eli Lilly collaborated with OmniAb in California to explore new therapies using OmniAb’s technology platform. Lilly could earn up to $370 million in milestone payments, in addition to undisclosed upfront support.
Conclusion
The landscape of biopharma deals in August 2026 showcases a blend of acquisitions and collaborations emphasizing innovation in disease treatment. With major companies actively pursuing strategic partnerships and mergers, the biopharmaceutical sector continues to evolve, promising advancements that could shape the future of medicine.
- Major acquisitions included Eli Lilly’s purchase of Merida Biosciences and Jazz Pharmaceuticals’ acquisition of Actio Biosciences.
- Partnerships between companies like Genentech and DualityBio highlight a focus on developing antibody-drug conjugates.
- Ongoing collaborations surrounding ion channels and peptide therapies are paving the way for breakthroughs in neurological and metabolic conditions.
Read more → www.labiotech.eu
